Axsome Therapeutics (AXSM) said Monday it received feedback from the US Food and Drug Administration supporting a submission of its drug for Alzheimer's disease agitation for approval.
Meeting minutes from the company's pre-new drug application huddle with the FDA indicated that the company's regulatory data package for AXS-05 would support a supplemental new drug application, the company said.
The company said it anticipates making such a submission in Q3.
The treatment holds the FDA's breakthrough therapy designation and will be eligible for a priority review, Axsome noted.
Price: 129.00, Change: +1.46, Percent Change: +1.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。